Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo, Background PAH Therapy; Biological · Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more

Conditions: Acute Spinal Cord Injury
Interventions: Perflutren Lipid Microsphere; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: Left ventricular assist device (LVAD), Tricuspid Valve Repair (TVR); Device · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
Interventions: Itacitinib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Menorrhagia, Heavy Menstrual Bleeding
Interventions: Tranexamic acid tablets (XP12B); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 47 more

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions: Intravenously administered pooled human immunoglobulin (IVIG); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more

Conditions: Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions: Ribavirin, Telaprevir, Pegylated interferon alfa-2a; Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 34 more

Conditions: HIV/AIDS
Interventions: Individual Telephone Counseling Intervention, Group Arm, Book Arm; Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: HIV Infections
Interventions: JS7 DNA vaccine, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • San Francisco, California • Seattle, Washington

Conditions: Atopic Dermatitis
Interventions: ADX-914, Placebo; Drug
Lead sponsor: Q32 Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 20 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more

Conditions: Alcohol; Use, Problem
Interventions: Experimental: Mobile Alcohol Expectancy Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 25 Years
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Lesions
Interventions: Hybrid ESD, Non-hybrid ESD; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Orlando, Florida • Fort Wayne, Indiana + 2 more

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Lymphoma, Mantle Cell
Interventions: Acalabrutinib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 65 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Downey, California • Santa Monica, California + 27 more

Conditions: Endometrial Cancer
Interventions: Facilitated group support, 1:1 Peer Support; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Miami, Florida + 8 more

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions: tosedostat, cytarabine, decitabine; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Cancer
Interventions: Ruxolitinib, Placebo, Capecitabine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 153
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions: Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 36
States / cities: Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more

Search by objective public record fields.

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

tSCI Contrast Enhanced Ultrasound Study

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Safety Study of XP12B in Women With Menorrhagia

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Self-Managing HIV and Chronic Disease

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Early Immune Responses to Vaccination - A Substudy to HVTN 205

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences

Hybrid Versus Non-Hybrid Endoscopic Submucosal Dissection for Colorectal Polyps (SHORT-ESD)

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma